drugset / Trial / NCT00713791

Relative Bioavailability Study in Healthy Male Subjects for ZD4054 (Zibotentan) Immediate Release Tablets.

NCT00713791

Phase 1 Completed 20 enrolled AstraZeneca
RandomizedCrossoverSingle-blindBasic science

Summary

This study is designed to see how different formulations of ZD4054 (Zibotentan) are absorbed by the body. As for all clinical trials, safety and tolerability of the drug will be evaluated.

Timeline

Start
2008-06
Primary completion
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Zibotentan Small molecule 10 mg Oral

Indications

No indication recorded.